about
Characterization of the imprinted polycomb gene L3MBTL, a candidate 20q tumour suppressor gene, in patients with myeloid malignanciesSomatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevanceEpigenetic regulators as promising therapeutic targets in acute myeloid leukemiaThe JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemiaInhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemiaActivating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisFoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stressGenome-wide analysis of transcriptional reprogramming in mouse models of acute myeloid leukaemiaRequirement for CDK6 in MLL-rearranged acute myeloid leukemia.Cytogenetics of chronic myeloid leukaemia.A Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment.A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factorsDoes isochromosome 7q mandate bone marrow transplant in children with Shwachman-Diamond syndrome?Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia.Somatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5(+/-) leukemia.A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression.The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.Targeting cancer stem cells.HOX gene regulation in acute myeloid leukemia: CDX marks the spot?Leukemia stem cells in acute myeloid leukemia.Network properties derived from deep sequencing of human B-cell receptor repertoires delineate B-cell populationsFumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transitionHOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias.A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation.Recent advances in acute myeloid leukemia stem cell biologyTargeting epigenetic readers in cancer.Disordered signaling in myeloproliferative neoplasms.Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis.The transcriptional coactivator Cbp regulates self-renewal and differentiation in adult hematopoietic stem cells.BET bromodomain inhibitors in leukemia.Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors.A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.Mll-AF4 Confers Enhanced Self-Renewal and Lymphoid Potential during a Restricted Window in Development.Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemiaAcute myeloid leukemia: leukemia stem cells write a prognostic signature.Functional interdependence of BRD4 and DOT1L in MLL leukemia.Modeling the evolution of ETV6-RUNX1-induced B-cell precursor acute lymphoblastic leukemia in mice.Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesis.
P50
Q24317211-8DCB57AF-1294-4986-B50F-FDCEB36FB415Q24568313-41465F78-63BF-4322-8F9A-5113515E03F3Q26776393-9BA72302-4A72-4C59-A817-25F28EB9C42DQ26865149-C9F90456-1CB2-4411-8E56-95E76B5148DDQ27266125-F4BDFAE8-A618-4708-BD40-A7817277F222Q27674674-FBA1C8DD-D88A-4035-9D06-1A4CA872513DQ29614337-E13337D6-F827-4677-96EF-D4F0F6D5B457Q29615562-7ECBD862-C24D-4155-8A2D-5A345B98B500Q33813024-C62FF57D-582A-418C-B9B8-2B5EDFF0806CQ34310186-9437DB1F-FA57-4059-B3E0-C17C6D9760B7Q34407432-671658E8-AEB4-424A-9D51-31BA754F4491Q34433236-8308A149-3EDD-40D9-9145-E11AFCEFEA3EQ34543038-FE2E3198-CE42-454F-B679-808A2FDD4F24Q34806728-76FDC131-F37B-4355-AD3A-73C3E24F3131Q35020669-74CBE3AF-CB8E-4469-9A2F-4813D1983008Q35120932-07DB92F3-BAC2-4139-AF38-B807CE1DF3BFQ35744654-B31FC4FE-DD65-4A82-8E6C-9879FA55985CQ36080675-F1ADE8C9-3E3C-49BF-9F7B-47BAE4D9FEF5Q36508924-CE09D718-15A1-423B-A613-4A0D7B4B3256Q36871985-99DB305A-BB25-4181-A015-DF7F8AF784B1Q36946427-DB502CA2-E229-4D57-89EC-BF3A2A0B56F0Q37240549-49896BB2-7B1C-4270-9FCC-7D1D22B06E12Q37272443-D7785D00-7828-4DFC-BC13-8AC3722F45FBQ37470652-95BF2958-05BD-43C5-8414-FF067BC3DA8CQ37503220-1A0D986F-6D0A-4C79-8E06-5FC616FF700DQ37740931-5256A2FB-9B40-4E00-BD92-EB4DF218B516Q38003359-09156589-9709-4D81-8387-43DB8E435701Q38034797-C9A73D9B-657C-4360-936E-447E27E072B9Q38046315-331622A9-D401-4DC8-BE41-6DA5EB2C4451Q38303954-BDDD694E-6F4C-4FED-8F40-A59054851795Q38331056-D4E8FD03-7871-40A5-8C97-07C584C58F77Q38545211-06165E69-BAFD-43D8-A1B9-E229D0598A3BQ38616272-B8DA610D-6FDA-46AE-A955-024FC263BF6BQ38695117-A3DFADBC-8438-437E-BAB7-4CC5C48383E3Q38843624-6D557ADC-95DC-43F6-93C1-C9E09D29BBF9Q39063991-AE18988B-6728-42AA-8F7F-32B249674F5FQ39448082-5B27AD46-37D0-461D-A1DD-85ADCD8413C8Q39688289-86A86332-5C61-48D1-9274-8BBE5B907D05Q39746689-182F4CF1-DFCD-4BA7-ABD6-B970CD00CE48Q42415927-54861141-505A-41BF-9DB9-D69C53826EB5
P50
description
researcher ORCID ID = 0000-0003-0312-161X
@en
name
Brian Huntly
@ast
Brian Huntly
@en
Brian Huntly
@es
Brian Huntly
@nl
type
label
Brian Huntly
@ast
Brian Huntly
@en
Brian Huntly
@es
Brian Huntly
@nl
prefLabel
Brian Huntly
@ast
Brian Huntly
@en
Brian Huntly
@es
Brian Huntly
@nl
P108
P108
P31
P496
0000-0003-0312-161X